Company intelligence / Profile preview
Tianjin PuYing Biotechnology
Tianjin, Tianjin, Chinacassie12117.en.ec21.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tianjin PuYing Biotechnology has advanced a recombinant human serum albumin/granulocyte colony-stimulating factor fusion protein into Phase IIb clinical trials for the prevention of chemotherapy-induced neutropenia in breast cancer patients. Another pipeline asset, an albumin-interferon alpha2b fusion protein, targets hepatitis B and appears to be in preclinical or pending status. No published late-stage or commercial results as of June 2025
- Therapeutic areas
- HematologyInfectious Diseases
- Modalities
- Recombinant fusion proteinBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Not publicly disclosed as of June 2025
Beyond the preview
Go deeper on Tianjin PuYing Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tianjin PuYing Biotechnology.